RedHill Biopharma Submits COVID-19 Clinical Trial Application for Phase 2/3 Study with Opaganib
The multi-center, randomized, double-blind, parallel-arm, placebo-controlled Phase 2/3 clinical study of opaganib for severe COVID-19 patients is planned to be […]